InsiderTrades

Form 4 for GILD Gilead Sciences

Accepted 2026-03-12 00:00:00 ET · period of report 2026-03-10 · accession 0001739515-26-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-03-12 2026-03-10 GILD Berger Dietmar Chief Medical Off M - OptEx — +2,133 20.0K +12% —
D 2026-03-12 2026-03-10 GILD Berger Dietmar Chief Medical Off F - Tax $148.56 -1,063 19.0K -5% -$157.9K
D 2026-03-12 2026-03-10 GILD Berger Dietmar Chief Medical Off M - OptEx — -2,133 39.0K -5% —
DM 2026-03-12 2026-03-10 GILD Berger Dietmar Chief Medical Off A - Grant $0.00 +39.9K 47.5K +527% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-10 M A 2,133 — 20,045 D — — (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2 Common Common Stock 2026-03-10 F D 1,063 $148.56 18,982 D — —
3 Derivative Restricted Stock Unit 2026-03-10 M D 2,133 — 39,046 D — · — to — 2,133 Common Stock (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
4 Derivative Non-qualified Stock Option (Right to Buy) 2026-03-10 A A 31,475 $0.00 31,475 D $148.56 · — to 2036-03-10 31,475 Common Stock (F3) The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
5 Derivative Restricted Stock Unit 2026-03-10 A A 8,415 — 47,461 D — · — to — 8,415 Common Stock (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.